---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-047920"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:50:40.814584+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q3 net loss $21.8M ($1.84/sh); PBGENE-HBV doses Cohort 3, PBGENE-DMD IND on track

## Summary
- Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.
- Revenue <$0.1M, down from $0.6M YoY; R&D $13.4M, G&A $7.3M.
- Cash $71.2M; expected runway into H2 2027 via cost cuts and potential near-term CAR T payments.
- PBGENE-HBV Phase 1 dosing Cohort 3; late-breaking oral at AASLD on Nov 10.
- PBGENE-DMD IND filing expected end-2025; Phase 1 start H1 2026, initial data H2 2026.

## SEC filing metadata
- accession: 0001628280-25-047920
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/0001628280-25-047920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828025047920/dtil-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-047920
- JSON: https://secwatch.observer/filing/0001628280-25-047920.json
- Plain text: https://secwatch.observer/filing/0001628280-25-047920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.